Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: A feasibility study

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Clausen, Malene M ^a,b   Hansen, Anders E ^b,c   af Rosenschold, Per M ^a,d   Kjær, Andreas ^b   Kristensen, Annemarie T ^b   McEvoy, Fintan J ^b   Engelholm, Svend A ^a  

^a Rigshospitalet   (Denmark)

^b Nuclear Medicine and PET and Cluster for Molecular Imaging ^*  (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIACETYL BIS N4 METHYLSEMITHIOCARBAZONE CU 64; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CANINE MODEL; COMPUTED TOMOGRAPHY SCANNER; DRUG DOSE ESCALATION; DRUG TUMOR LEVEL; FEASIBILITY STUDY; FIBROSARCOMA; GLYCOLYSIS; HEMANGIOPERICYTOMA; HYPOXIA; NON INVASIVE PROCEDURE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIOTHERAPY SOFTWARE; SOFT TISSUE SARCOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING; TUMOR VOLUME;

ALGORITHMS; ANIMALS; ANOXIA; COPPER RADIOISOTOPES; DOGS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUORODEOXYGLUCOSE F18; GLYCOLYSIS; MULTIMODAL IMAGING; NEOPLASMS; NORMAL DISTRIBUTION; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; THIOSEMICARBAZONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887339426     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-262     Document Type: Article

References (35)

1. Bentzen S. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005, 6(2):112-117. 10.1016/S1470-2045(05)01737-7, 15683820.
2. Brahme A, Agren A. Optimal dose distribution for eradication of heterogenous tumours. Acta Oncol 1987, 26(5):377-385. 10.3109/02841868709104364, 3426851.
3. Malinen E, et al. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006, 51(19):4903-4921. 10.1088/0031-9155/51/19/012, 16985278.
4. Søvik T, et al. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol 2007, 52(2):499-513. 10.1088/0031-9155/52/2/013, 17202629.
5. Ling CC, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47(3):551-560. 10.1016/S0360-3016(00)00467-3, 10837935.
6. Thorwarth D, Geets X, Paiusco M. Physical radiotherapy treatment planning based on functional PET/CT data. Radiother Oncol 2010, 96(3):317-324. 10.1016/j.radonc.2010.07.012, 20673689.
7. Meijer G, et al. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp brush. Radiother Oncol 2011, 100(3):396-401. 10.1016/j.radonc.2011.08.048, 21955663.
8. Alber M, et al. On biologically conformal boost dose optimization. Phys Med Biol 2003, 48(2):N31-N35. 10.1088/0031-9155/48/2/404, 12587912.
9. Allal AS, et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18 F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004, 59(5):1295-1300. 10.1016/j.ijrobp.2003.12.039, 15275712.
10. Koukourakis MI. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) Are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006, 24(5):727-735. 10.1200/JCO.2005.02.7474, 16418497.
11. Nordsmark M, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24. 10.1016/j.radonc.2005.06.038, 16098619.
12. Dehdashti F, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003, 30(6):844-850. 10.1007/s00259-003-1130-4, 12692685.
13. Clavo A, Brown R, Wahl R. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995, 36:1625-1632.
14. Busk M, et al. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008, 35(12):2294-2303. 10.1007/s00259-008-0888-9, 18682937.
15. Busk M, et al. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 2008, 122(12):2726-2734. 10.1002/ijc.23449, 18351643.
16. Pugachev A, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005, 62(2):545-553. 10.1016/j.ijrobp.2005.02.009, 15890599.
17. Dence CS, et al. Autoradiographic and small-animal PET comparisons between 18 F-FMISO, 18 F-FDG, 18 F-FLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol 2008, 35(6):713-720. 10.1016/j.nucmedbio.2008.06.001, 2661147, 18678357.
18. O'Donoghue JA, et al. Assessment of regional tumor hypoxia using 18 F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61(5):1493-1502. 10.1016/j.ijrobp.2004.12.057, 15817355.
19. Christian N, et al. Is 18 F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer 14C-EF3 in animal tumor models. Radiother Oncol 2010, 97(2):183-188. 10.1016/j.radonc.2010.02.020, 20304513.
20. Hansen AE, et al. (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiation oncology 2012, 7:89. 10.1186/1748-717X-7-89, 3403947, 22704363.
21. Hansen AE, et al. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol 2012, 102(3):424-428. 10.1016/j.radonc.2011.10.021, 22119225.
22. Bowen SR, et al. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol 2011, 38(6):771-780. 10.1016/j.nucmedbio.2011.02.002, 3157049, 21843774.
23. Dibble EH, et al. 18 F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012, 53(5):709-715. 10.2967/jnumed.111.099531, 22492732.
24. Thorwarth D, et al. Combined uptake of [18 F]FDG and [18 F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006, 80(2):151-156. 10.1016/j.radonc.2006.07.033, 16920211.
25. Reese AS, et al. Integral dose conservation in radiotherapy. Med Phys 2009, 36(3):734. 10.1118/1.3070585, 19378734.
26. Dehdashti F, et al. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008, 49(2):201-205. 10.2967/jnumed.107.048520, 18199612.
27. Vansteenkiste J, et al. Prognostic importance of the standardized uptake value on 18 F-Fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. J Clin Oncol 1999, 17:3201-3206.
28. Mortensen LS, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 2012, 105(1):14-20. 10.1016/j.radonc.2012.09.015, 23083497.
29. Due A, et al. Oc-0148 head and neck cancer recurrence density in relation to Fdg-Pet and clinical imrt target volumes. Radiother Oncol 2012, 103:S57.
30. Bentzen SM, et al. Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys 2007, 69(2 Suppl):S79-S82.
31. Madani I, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68(1):126-135. 10.1016/j.ijrobp.2006.12.070, 17448871.
32. van Elmpt W, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012, 104(1):67-71. 10.1016/j.radonc.2012.03.005, 22483675.
33. Kofler B, et al. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Oto-rhino-laryngol 2013, DOI 10.1007/s00405-013-2603-0.
34. Bentzen SM. Radiation therapy: Intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 2005, 77(3):227-230. 10.1016/j.radonc.2005.11.001, 16300846.
35. Fatyga M, et al. A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: A radiobiological modeling study. Med Phys 2009, 36(9):3995. 10.1118/1.3187224, 2738740, 19810472.